The trial investigators reported a lower incidence of self-reported colds in the probiotic arm. Over 12 weeks, the group receiving Lactiplantibacillus plantarum LP28 had a cold incidence of 34.78%, compared with 52.00% in the placebo group. Symptom burden was assessed with the Wisconsin Upper Respiratory Symptom Survey (WURSS); the probiotic cohort showed a lower cumulative symptom load according to the authors. The study team used a refined per-protocol approach and outlier-removed sensitivity analyses to test the robustness of these clinical findings.
Short, objective statements: the probiotic group experienced fewer cold episodes. The trial report did not provide detailed attack-rate timing or pathogen confirmation by PCR, so interpretation is limited to clinically reported upper respiratory events as captured by WURSS.
Investigators measured circulating cytokines, immune-cell populations and functional NK assays. The probiotic arm exhibited a significant increase in serum interleukin-12 (IL-12) levels; the study team observed a parallel enhancement in NK cell cytotoxicity measured by NK cell cytotoxicity assays. These results, the authors argue, point to activation of an IL-12/NK cell axis that could strengthen innate defense against respiratory pathogens.
Data indicated a concomitant reduction in C-reactive protein (CRP) among those receiving LP28, suggesting lower systemic inflammatory stress during the intervention period. The report did not list detailed time-course plots for each biomarker nor provide mechanistic in vivo validation beyond the reported assays, so readers should interpret the biomarker changes in the context of the trial’s 12-week window.
This was a 12-week, randomized, double-blind, placebo-controlled trial. The cohort comprised middle-aged and older adults aged 50–75 years. The probiotic regimen was explicitly reported: 5 × 10^9 CFU Lactiplantibacillus plantarum LP28 per capsule, two capsules taken daily. Each arm included 51 participants at randomization.
Clinical endpoints included incidence of upper respiratory episodes and WURSS-derived symptom severity. Immune endpoints were quantified using flow cytometry for cell populations, ELISAs for soluble markers, and NK cytotoxicity assays for functional readouts. The authors analyzed data with independent t tests, chi-square or Fisher’s exact tests, and Mann-Whitney U tests as appropriate. They applied a refined per-protocol approach and conducted sensitivity analyses removing outliers to support the robustness of outcomes.
The manuscript states ethical oversight was provided by the Institutional Review Board of Taichung Veterans General Hospital (Protocol No. SF24108C) and lists trial registration NCT06724185. The data are available on request from the corresponding author, according to the report.
The source disclosed employment ties: three named authors are employed by SYNBIO TECH INC.; other authors declared no conflicts. The report provided no granular adverse-event table in the publicly available abstract text, and it did not enumerate serious adverse events within the summary. Investigators reported standard safety oversight and ethical approvals, but the preprint text did not include an explicit breakdown of tolerability metrics or event rates by system organ class; those details would require accessing the full manuscript or contacting the corresponding author.
Data availability is stated: interested researchers may request underlying datasets from the corresponding author. Short note on transparency: the trial was supported in part by a university–industry cooperation fund, as declared in the source.
The authors framed their conclusions around 12-week outcomes; the report did not present longer-term follow-up data beyond the study period. The trial relied on WURSS for symptom capture; pathogen confirmation (for example, viral PCR) was not reported in the source text. Detailed adverse-event breakdowns and explicit mechanistic dose–response curves were not included in the abstracted material available.
Unanswered questions that remain in this report include whether the observed biomarker shifts translate into durable protection beyond 12 weeks, how LP28 performs across different seasonal viral exposures, and whether specific subgroups (for example, frail elderly or those with chronic respiratory disease) show comparable benefit. The paper provides data on IL-12, NK cytotoxicity and CRP changes, but it does not report more granular immunophenotyping trajectories or confirm causality via mechanistic human studies within this dataset.
Limitations summarized: short intervention window in the available report, symptom-based rather than pathogen-confirmed endpoints, and incomplete adverse-event detail in the public abstract. For additional specifics or raw data, the corresponding author is the source contact as stated in the manuscript.